ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2039

Validity of the Wpai-SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference

William Tillett1,2, Gavin Shaddick3, Bashaar Boyce4 and Neil J. McHugh5, 1Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 2Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, 3Centre for Data Science and Statistics, University of Exeter, Bath, United Kingdom, 4Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: outcome measures and psoriatic arthritis, Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Measures and Measurement of Healthcare Quality Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Participation, including work disability, is an important patient centred outcome and is in the middle ring of the Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis core set of domains. The Work Productivity and Activity Index Specific Health Problem (WPAI-SHP) is a feasible, patient reported measure of work disability but there is little data on the validity of the WPAI-SHP in PsA. We set out to determine the validity of the WPAI-SHP and the minimally important difference (MID) for improvement in PsA.

Methods:

LOPAS II is a UK multicentre observational study of work disability in PsA. Working patients were included for analysis. Construct validity was determined by correlation with other clinical and patient reported outcomes using spearman correlation coefficients. Responsiveness was calculated using the standard error of the mean (SEM). The MID was determined by the health based anchor method (mean change in score amongst patients who improved) and the receiver operating characteristic curve (ROC) method.

Results:

Analyses were undertaken on 177 of 229(77.3%) working participants with complete data at baseline and three months follow up. The mean age was 48 years and median disease duration 6.0 years (IQR 2.0 – 12.0). The mean change of presenteeism was -7.9 (sd30.0), SEM 16.2 and SRM -0.26. Correlations with other outcomes are reported in table 1. Amongst 105 (59.3%) patients who reported no change between baseline and follow up the mean change in WPAI was; absenteeism 2.9 (sd30.7), presenteeism 4 (26.5), productivity loss 7.7 (27.2), activity impairment 1.9 (24.4). The MID for improvement amongst 72 (40.7) patients who reported improvement was; absenteeism -6.1 (26.2), presenteeism -20.8 (28.2), productivity loss -21.7 (30.8) and activity impairment -27.2 (29.5). The MID using the ROC method for presenteeism, productivity loss and activity impairment was -5.0 (AUC 0.75), -11.3 (AUC 0.76) and -25.0 (AUC 0.79) respectively (Figure 1).

Conclusion:

We report data on the validity of the WPAI-SHP in PsA and an estimate of the MID for improvement. Presenteeism and productivity loss are moderately correlated with clinical measures. Responsiveness was small to moderate amongst the group as a whole.

Table 1 Spearman correlation coefficients of the WPAI-SHP and clinical, composite and patient reported outcomes at baseline.

Outcomes

WPAI absenteeism

WPAI presenteeism

WPAI productivity loss

WPAI

activity impairment

DAPSA

0.20

0.34

0.39

0.45

RAPID3

0.32

0.54

0.62

0.77

HAQ

0.31

0.42

0.51

0.61

EQ5D

-0.29

-0.42

-0.44

-0.59

FACIT fatigue

-0.40

-0.44

-0.53

-0.61

Global VAS

0.26

0.47

0.52

0.70

Pain VAS

0.26

0.51

0.57

0.65


Disclosure: W. Tillett, Sonya Abraham, MRCP, PhD, 2,Sonya Abraham, MRCP, PhD, 5,Sonya Abraham, MRCP, PhD, 9; G. Shaddick, None; B. Boyce, None; N. J. McHugh, None.

To cite this abstract in AMA style:

Tillett W, Shaddick G, Boyce B, McHugh NJ. Validity of the Wpai-SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/validity-of-the-wpai-shp-in-psoriatic-arthritis-and-estimation-of-the-minimally-important-difference/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-of-the-wpai-shp-in-psoriatic-arthritis-and-estimation-of-the-minimally-important-difference/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology